Key result
ACEIs and ARBs are not linked to mortality or disease severity in COVID-19.
Why the study?
The study sought to explore the link between ACEI or ARB utilization and mortality, disease severity, and healthcare resource utilization in patients with COVID-19 to inform safe clinical medication use.
Does the use of ACEIs or ARBs influence mortality, severity, or healthcare resource utilization in patients with COVID-19?
Meta-Analysis
Does the use of ACEIs or ARBs influence mortality, severity, or healthcare resource utilization in patients with COVID-19?
Odds Ratio: 1.1 (95% CI 0.83–1.46)
p-value: p=0.43
The use of ACEIs and ARBs is not significantly correlated with mortality, severity, or healthcare resource utilization in patients with COVID-19, supporting the safe continuation of these medications during infection.
Supports safe continuation of ACEIs/ARBs during COVID-19; confirms neutral mortality effect in meta-analysis.
Objective: The primary objective of this study is to explore the potential link between the utilization of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and its impact on mortality, disease severity, and healthcare resource utilization in individuals diagnosed with COVID-19. We aim to establish a solid theoretical foundation for safe and effective clinical medications. Methods: We conducted a comprehensive search of various databases, including CNKI, PubMed, Science, Cell, Springer, Nature, Web of Science, and Embase. We also traced the literature of the included studies to ensure a thorough analysis of the available evidence. After applying a set of inclusion and exclusion criteria, we ultimately included a total of 41 articles in our analysis. To determine the overall effect size for dichotomous variables, we used the Mantel–Haenszel odds ratio in random effect models. For continuous variables, we calculated the inverse variance SMD using random effect models. To assess the outcomes and heterogeneity, we considered p-values (p < 0.05) and I2 values for all outcomes. We performed multivariate and univariate meta-regression analyses using the maximum likelihood approach with the CMA 3.0 software. Results: The results of our analysis indicated that the use of ACEIs or ARBs did not significantly influence mortality (OR = 1.10, 95% CI 0.83–1.46, p = 0.43, I2 = 84%), severity (OR = 0.99, 95% CI 0.68–1.45, p = 0.98, I2 = 84%), or healthcare resource utilization (SMD = 0.03, 95% CI 0.06–0.12, p = 0.54, I2 = 37%) in patients with COVID-19 compared to those not taking ACEIs or ARBs. The multivariate meta-regression analysis model explained 63%, 31%, and 100% of the sources of heterogeneity for the three outcome indicators. Conclusions: The use of ACEIs and ARBs is not significantly correlated with mortality, severity, or healthcare resource utilization in patients with COVID-19, indicating safe clinical use of the medications.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted a meta-analysis in COVID-19. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) vs. Not taking ACEIs or ARBs was evaluated on Mortality (OR 1.10, 95% CI 0.83-1.46, p=0.43). The use of ACEIs or ARBs was not significantly associated with mortality (OR 1.10; 95% CI 0.83-1.46; p=0.43), disease severity, or healthcare resource utilization in patients with COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: